The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Ipsen; Janssen; Novartis; Pfizer; Roche; Sanofi
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Ipsen; Janssen; Novartis; Pfizer; Roche; Sanofi
Sequential treatment with pazopanib followed by nivolumab in patients with renal cell carcinoma: Updated interim results of the non-interventional study PAZOREAL.
 
Jens Bedke
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; EUSA Pharma; Ipsen; MSD; Nektar; Novartis; Pfizer; Roche
Speakers' Bureau - Eisai; EUSA Pharma; Ipsen; MSD; Novartis; Pfizer; Roche
Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); Ipsen (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
 
Martin Boegemann
Honoraria - Amgen; Astellas Pharma; AstraZeneca; Bayer/Vital; Bristol-Myers Squibb; Eisai; EUSA Pharma; Ipsen; Janssen-Cilag; Merck; MSD; Novartis; Pfizer; Roche; Sanofi/Aventis
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; ipsen; Janssen-Cilag; Merck; MSD; Novartis; Roche; Sanofi
Research Funding - Janssen-Cilag
Travel, Accommodations, Expenses - Amgen; Bayer; Janssen-Cilag
 
Martin Schostak
Honoraria - AstraZeneca; Bristol-Myers Squibb; MSD; Novartis; Roche
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; MSD; Novartis
Research Funding - AstraZeneca; Bristol-Myers Squibb; MSD
 
Christiane Hering-Schubert
No Relationships to Disclose
 
Manfred Welslau
No Relationships to Disclose
 
Jan Schleicher
Honoraria - Celgene; Ipsen; Janssen-Cilag; Pfizer
Consulting or Advisory Role - Ipsen; Merck Sharp & Dohme; Novartis; Pfizer; Takeda
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Novartis (Inst)
 
Alexander Petzoldt
No Relationships to Disclose
 
Christian Doehn
Stock and Other Ownership Interests - AstraZeneca; AVEO
Honoraria - Bristol-Myers Squibb; Eisai; EUSA Pharma; Ipsen; Merck; MSD; Novartis; Pfizer; Roche
Consulting or Advisory Role - Bristol-Myers Squibb; Ipsen; MSD; Novartis; Pfizer; Roche; Takeda
 
Carsten Gruellich
Honoraria - Bristol-Myers Squibb; Eisai; Ipsen; MSD; Roche
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Eisai; Ipsen; MSD; Roche
Research Funding - Ipsen
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Eisai; Ipsen; Roche
 
Peter-Juergen Goebell
No Relationships to Disclose
 
Thomas Steiner
Employment - Fresenius
Stock and Other Ownership Interests - Fresenius
Consulting or Advisory Role - Bristol-Myers Squibb; Novartis
Research Funding - Bristol-Myers Squibb (Inst)
 
Elisa Degenkolbe
Employment - Novartis
 
Sven Hanson
Employment - Novartis
 
Viktor Grünwald
Stock and Other Ownership Interests - AstraZeneca; Bristol-Myers Squibb; MSD
Honoraria - Asklepios Kliniken; AstraZeneca; Bayer; Bristol-Myers Squibb; Clinic of Oldenburg; Diakonie Clinic; Dortmund Hospital; Eisai; EUSA Pharma; Ipsen; Janssen-Cilag; Lilly; Merck Serono; MSD Oncology; Novartis; Pfizer; PharmaMar; Roche
Consulting or Advisory Role - Bristol-Myers Squibb; Ipsen; Janssen-Cilag; Lilly; MSD Oncology; Novartis; Onkowissen; Pfizer
Research Funding - Novartis (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bayer; Bristol-Myers Squibb; Ipsen; Pfizer